Lupin Limited

NSE:LUPIN.NS

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

India

Market Cap

USD 10.27 B

Share Price

USD 22.49

Avg Daily Volume

1,090,660

Change (1 day)

0.94%

Change (1 year)

20.93%

Change (YTD)

-18.29%

Lupin Limited Accounts Payable for the year ending March 31, 2025: USD 346.16 M

Lupin Limited Accounts Payable is USD 346.16 M for the year ending March 31, 2025, a -2.39% change year over year. Accounts payable are amounts owed by the company to suppliers or vendors for goods or services received but not yet paid.

Lupin Limited Accounts Payable for the year ending March 31, 2024 was USD 354.65 M, a 15.14% change year over year.
Lupin Limited Accounts Payable for the year ending March 31, 2023 was USD 308.01 M, a 2.45% change year over year.
Lupin Limited Accounts Payable for the year ending March 31, 2022 was USD 300.66 M, a 9.29% change year over year.
Lupin Limited Accounts Payable for the year ending March 31, 2021 was USD 275.11 M, a -14.06% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Accounts Payable	Short-Term Debt	Long-Term Debt	Total Liabilities

NSE: LUPIN.NS

Lupin Limited

CEO	Ms. Vinita D. Gupta
IPO Date	Sept. 10, 2001
Location	India
Headquarters	Kalpataru Inspire
Employees	19,210
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.